Cargando…

Ethnic Variation of TET2 SNP rs2454206 and Association with Clinical Outcome in Childhood AML: A Report from the Children’s Oncology Group

Detalles Bibliográficos
Autores principales:	Kutny, Matthew A., Alonzo, Todd A., Gamazon, Eric R., Gerbing, Robert B., Geraghty, Daniel, Lange, Beverly, Heerema, Nyla A., Sung, Lillian, Aplenc, Richard, Franklin, Janet, Raimondi, Susana C., Hirsch, Betsy A., Konkashbaev, Anuar, Cox, Nancy J., Onel, Kenan, Gamis, Alan S., Meshinchi, Soheil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675677/ https://www.ncbi.nlm.nih.gov/pubmed/26126966 http://dx.doi.org/10.1038/leu.2015.171

Ejemplares similares

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
por: Aplenc, Richard, et al.
Publicado: (2020)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group
por: Vujkovic, Marijana, et al.
Publicado: (2016)

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2015)

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2016)

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group
por: Nagarajan, Rajaram, et al.
Publicado: (2019)

ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial
por: Rafiee, Roya, et al.
Publicado: (2019)

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
por: Voigt, Andrew P., et al.
Publicado: (2017)

Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study
por: Ho, Phoenix A., et al.
Publicado: (2010)

Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival
por: Pommert, Lauren, et al.
Publicado: (2022)

Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia
por: Narayanan, P., et al.
Publicado: (2021)

Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children’s Oncology Group report
por: Long, Xin, et al.
Publicado: (2017)

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
por: Lim, Emilia L., et al.
Publicado: (2017)

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study
por: Hoff, Fieke W., et al.
Publicado: (2022)

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG
por: Rasche, Mareike, et al.
Publicado: (2021)

Merging Children’s Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children’s Oncology Group
por: Li, Yimei, et al.
Publicado: (2015)

Early discharge as a mediator of greater ICU‐level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report
por: Getz, Kelly D., et al.
Publicado: (2016)

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
por: Huang, Benjamin J., et al.
Publicado: (2021)

Evidence of selection on splicing-associated loci in human populations and relevance to disease loci mapping
por: Gamazon, Eric R., et al.
Publicado: (2017)

Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group
por: Johnston, Donna, et al.
Publicado: (2015)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
por: Huang, Benjamin J., et al.
Publicado: (2022)

Transcriptome Profiling of Pediatric Core Binding Factor AML
por: Hsu, Chih-Hao, et al.
Publicado: (2015)

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
por: Farrar, Jason E., et al.
Publicado: (2023)

A B-cell developmental gene regulatory network is activated in infant AML
por: Bolouri, Hamid, et al.
Publicado: (2021)

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
por: Huang, Feiteng, et al.
Publicado: (2020)

Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient
por: Ma, Qiang, et al.
Publicado: (2021)

SCAN database: facilitating integrative analyses of cytosine modification and expression QTL
por: Zhang, Wei, et al.
Publicado: (2015)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Text Mining and Data Modeling of Karyotypes to aid in Drug Repurposing Efforts
por: Abrams, Zachary B., et al.
Publicado: (2015)

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2021)

Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre‐leukaemic clone resulting in T2‐ALL and AML‐M0
por: Manchev, Vladimir T., et al.
Publicado: (2016)

Promyelocytic Leukemia with No Retinoic Acid Receptor Alpha Abnormality but with RUNX1T1 Insertion to Chromosome 7q: A Classification and Management Dilemma
por: Overholt, Kathleen, et al.
Publicado: (2015)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
por: McNeer, Nicole A., et al.
Publicado: (2019)

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
por: Stirewalt, D L, et al.
Publicado: (2014)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

Novel t(1;2)(p36.1;q23) and t(7;19)(q32;q13.3) chromosomal translocations in ischemic fasciitis: expanding the spectrum of pseudosarcomatous lesions with clonal pathogenetic link
por: Sachak, Taha, et al.
Publicado: (2018)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection
por: Lavery, Hugh J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_je8u08dj5o9poi181gfr355v34